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Background: While research has established that the bedside electrocardiogram (ECG) is an 
insensitive test for the presence or absence of left ventricular hypertrophy (LVH), the finding, when 
present, is thought to be reproducible. 
Objective: To assess the reproducibility of serial ECGs done in the emergency department (ED) with 
regard to the presence or absence of LVH.
Method: A prospective study on consecutive patients admitted to an ED-run cardiac observation unit. 
A single reviewer collected and scored ECGs for the presence of LVH, using three established criteria 
(Cornell, Sokolow-Lyon and Romhilt-Estes). Demographic and medical history was also collected.
Results: Over a three-year time period, 295 patients were enrolled; 132 males and 163 females with 
a mean age of 54.4 years (range, 19-89 years). The prevalence of LVH ranged from 11-14% and the 
agreement among all three criteria was fair (kappa = 0.325). Using the Cornell criteria, 33 patients 
had ECG#1 consistent with LVH. Of the patients meeting LVH criteria on ECG #1, only 15 retained 
their diagnosis of LVH on ECG#2 (i.e. 55% of the LVH identified in ECG#1 was not seen in ECG#2). 
Additionally, nine patients developed an ECG diagnosis of LVH between ECG#1 and ECG#2. In total, 
27 (nine percent of the total) had ECG measurements that changed between ECG#1 and ECG#2. We 
made similar findings with the Sokolow-Lyon and Romhilt-Estes criteria. The results were not modified 
by gender, blood pressure or medication use. 
Conclusion: The finding of LVH on ECG was not very reproducible during serial measurements on 
the same person during a single 24-hour observation period. 
[WestJEM. 2009;10:140-143]
INTRODUCTION
The presence of left ventricular hypertrophy (LVH) 
has been reported to carry significant cardiovascular risk.1-5 
Although echocardiography and cardiac MRI are superior 
to electrocardiogram (ECG) for the diagnosis of LVH, these 
modalities are not readily available in the emergency department 
(ED).6-9 Instead, emergency physicians (EP) rely on ECG when 
risk stratifying a patient who presents with acute chest pain. 
The need to use this rapid bedside test to make the diagnosis of 
LVH has led to the development of multiple tools to interpret 
LVH on ECG, e.g. Cornell voltage, Sokolow-Lyon and Romhilt-
Estes criterion. The specificities of these tools are high (>90%), 
but the sensitivities are low (20-60%).10-14 In at least one large 
retrospective study, the overall sensitivity of ECG diagnosis of 
LVH was found to be 6.9%.15 In addition, the findings of LVH on 
ECG may resolve over time. A number of studies have described 
patients diagnosed with LVH using ECG technology only to 
show significant regression with appropriate anti-hypertensive 
treatment during subsequent years.16-20
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stratify individuals presenting with acute chest pain, the test 
should be reproducible during the course of a single ED visit. 
Previous authors have demonstrated that a single ECG is not a 
sensitive measure of LVH, but there is no published data on the 
reproducibility of serial ECGs in the acute setting. We undertook 
a prospective study using ED patients presenting with chest pain 
to examine the reproducibility of serial ECGs to identify LVH. 
METHODS
Study Population
This was a convenience sample of patients presenting to a 
large, urban ED with a chief complaint of chest pain. Patients 
were included in the study if they had a minimum of two 
electrocardiograms performed to rule out a myocardial infarction 
in the ED and/or the adjacent ED-run chest pain unit (CPU). 
Participants were excluded if their electrocardiograms were 
unreadable due to poor technique or if the patient had bundle 
branch or atrio-ventricular block on ECG. 
Study Design
Data was gathered prospectively as patients were admitted to 
the departmental CPU. We collected demographic information, 
clinical data and copies of standard 12-lead electrocardiograms 
during the ED/CPU stay. Vital signs and pertinent medications, 
specifically the use of digitalis, were abstracted from the medical 
charts. A single EP independently read and interpreted each 
ECG for the presence or absence of LVH using (a) the Cornell 
voltage criteria, (b) the Sokolow-Lyon voltage criteria, and (c) the 
Romhilt-Estes score. According to the Cornell voltage criteria, 
LVH is present if the sum of RaVL and SV3 is greater than or equal 
to 28 mm in men and 20 mm in women. The Sokolow-Lyon 
voltage criteria identify LVH when either RaVL is greater than 
1.1mV or the sum of SV1 and RV5 or RV6 is greater than or equal to 
3.5 mV. The Romhilt-Estes point score system determines LVH 
to be probable for four points and definite for five or more points; 
however, we combined those individuals with Romhilt-Estes 
scores of four and five into an LVH (+) classification. Previous 
authors have used this threshold of ≥four to ease interpretation 
and assess the true prevalence and cardiovascular risk associated 
with LVH.21 The EP interpreting the electrocardiograms was 
blinded to all data except gender and the use of digitalis. 
Statistical Analysis
We performed statistical analysis using STATA 9.0 software 
(College Station, TX), and generated a Kappa statistic to test 
the agreement between the Cornell voltage criteria, Sokolow-
Lyon criteria, and the Romhilt-Estes score. We then used logistic 
regression analysis to study the associations between change in 
criteria determination from ECG #1 to ECG #2 and age, race, gender 
and the change in mean arterial pressure from ECG #1 to ECG #2.
RESULTS
Between December 2004 and May 2007, 295 patients were 
included in the study; 132 males and 163 females with a mean 
age of 54.4 years (range, 19-89 years) (Table 1). Most of the 
patients were Latinos (65%) and ranged from 50-69 years old 
(60%).
Table 3. Change in LVH status from ECG time #1 to ECG time #2 
by criteria
Criteria Used
LVH (+) to LVH (-)
N (%)
LVH (-) to LVH (+)
N (%)
Cornell 18 (55) 9 (3)
Sokolow-Lyon 14 (35) 11 (4)
Modified Romhilt-Estes 18 (51) 5 (2)
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Table 1. Demographic characteristics of study participants
Variable N (%)
Gender
Male  132 (44.75)
Female 163 (55.25)
Ethnicity
Asian 21 (7.12)
Black 54 (18.31)
Hispanic 192 (65.08)
White 19 (6.44)
Other/Unknown 9 (3.05)
Age
<20 years 1 (0.34)
20-29 years 8 (2.71)
30-39 years 22 (7.46)
40-49 years 61 (20.68)
50-59 years 102 (34.58)
60-69 years 74 (25.08)
>70 years 26 (8.81)
Average 54.44
Range 19 - 89
Table 2. Percentages of LVH (+) and LVH (-) by criteria at ECG #1*
Criteria Used
LVH (+)
N (%)
LVH (-)
N (%) Total
Cornell 33 (11) 262 (89) 295
Sokolow-Lyon 40 (14) 255 (86) 295
Modified Romhilt-Estes 35 (12) 260 (88) 295
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Table 2 details the prevalence of LVH in the population for 
each of the three criteria used. Overall, the prevalence ranged 
from 11-14% in our patient population. The agreement between 
the three criteria was fair (kappa = 0.325). When using the 
Cornell criteria, 33 patients (11%) tested positive for LVH on 
ECG#1 and 262 had no evidence of LVH on ECG#1. Only 15 
of 33 (45%) who tested positive for LVH on ECG#1 retained 
their original diagnosis on ECG#2. Furthermore, nine patients 
out of 262 (3%) who tested negative for LVH during ECG#1 
subsequently tested positive during ECG#2. In total, 27 patients 
(9% of the total) had ECG measurements that changed between 
ECG#1 and ECG#2. We noted similar findings with all three 
criteria used, although neither the Sokolow-Lyon criteria nor the 
modified Romhilt-Estes criteria demonstrated such a dramatic 
change (Table 3).
To explain the variation seen in ECG criteria for LVH over 
time, we controlled for the mean arterial pressure (MAP) during 
analysis; however, we saw no consistent effect (data not shown). 
Age, gender and ethnicity also had no effect on our findings.
DISCUSSION 
When evaluating an ED patient with chest pain, EPs risk-
stratify patients to estimate probability of a diagnosis of acute 
coronary syndrome. One data point in this decision is the 12-lead 
ECG. Since LVH is known to be an independent predictor of future 
cardiovascular events and all-cause mortality, its identification 
on ECG implies increased risk to the patient, thus necessitating 
a more extensive patient work-up. Unfortunately, this logic has 
been challenged by recent research that suggests ECG technology 
provides an insensitive marker for the presence or absence of 
LVH.10-14 It also appears that there is a large degree of variability 
from ECG to ECG within the same individual. Three previous 
reports describe the variability of electrocardiographic diagnosis 
of LVH.22-24 These studies demonstrate inconsistent amplitude 
and duration of P waves, QRS complexes and ST and T wave 
measurements in certain leads during ECGs taken minutes to 24 
hours apart on the same person. If ECG is used to risk stratify 
an individual with possible acute coronary syndrome, then it is 
important that the test be reproducible. 
The presence of LVH has been shown to predict a higher 
rate of future cardiovascular events compared to those patients 
without LVH. In a sample of men, De Bacquer et al.1 (using 
Sokolow-Lyon) demonstrated that ECG diagnosed LVH was 
significantly associated with cardiovascular disease death (RR 
= 3.14). In a different multicenter study of patients presenting to 
the ED with symptoms of acute coronary syndrome, Pope et al.3 
(using Cornell voltage) found that patients with ECG-LVH were 
six times as likely to have a confirmed diagnosis of congestive 
heart disease and three times as likely to have hypertension. In 
addition, they discovered the 30-day mortality among patients 
with ECG-LVH was 4.6%. Mansoor et al.25 (using Sokolow-
Lyon) describe rates of hypertension complications, which 
include stroke, hypertensive heart failure and myocardial 
infarction, retinopathy, and aortic aneurysm, to be two to four 
times higher in patients with ECG-LVH.25 This effect has 
been demonstrated in multiple populations including patients 
with renal disease, the elderly and those with coronary artery 
disease.4,7,26 
The presence of LVH has also been considered a marker 
of sustained hemodynamic and neurohormonal stress on the 
myocardium.4 In the Health Outcomes Prevention Evaluation trial 
(using Sokolow-Lyon), LVH was present in 8.3% of a high-risk 
population undergoing treatment with ACE inhibitors. Patients 
had a single ECG performed at the time of randomization that was 
read by the local site investigator. For those patients with ECG 
measurements demonstrating evidence of LVH, the relative risk 
(RR) of sustaining a major CV event was 1.3 compared to those 
patients without LVH and the RR of all-cause death was 1.53.4
In our study of patients presenting to an ED with acute chest 
pain, diagnostic changes occurred in the interpretation of ECG#1 
versus ECG#2 regarding LVH in approximately nine percent of 
patients; thus, the test was reproducible in 91% of the total patient 
population. However, in those patients that tested positive for 
LVH in ECG#1 using Cornell criteria, only 45% retained findings 
of LVH on ECG#2. Similarly, three percent of patients who 
tested negative for LVH in ECG#1 subsequently tested positive 
after ECG#2. We noted similar findings using Sokolow-Lyon 
criteria and the modified Romhilt-Estes criteria. While we did 
not investigate the reason for these changes, potential variables 
include situational stress, transient or untreated hypertension, lead 
placement, or underlying heart disease.
As mentioned, one possible explanation for the misdiagnosis 
of LVH in our patient population is lead placement. Angeli et 
al.23 demonstrated the profound effect that lead placement can 
have on the presence of LVH by repeating electrocardiograms 
on hypertensive patients within 24 hours. Compared to our 
study, they found a similar proportion of patients changed their 
classification of LVH from the first to the second ECG. In 1990, 
Farb et al.24 demonstrated a high variability in the measurement 
of LVH when serial ECG measurements were separated by 
eight days. Although the lead to lead variability was high in that 
study, only two to three percent of individuals were reclassified 
as having LVH or not. Therefore, one approach to minimize the 
type of variability would be to leave the leads in place during the 
entire ED/CPU visit. 
LIMITATIONS
A primary limitation of this study was that we did not confirm 
the presence of LVH with an echocardiogram in real time; so we 
have no gold standard against which to judge the accuracy of 
the ECG in making the diagnosis of LVH. In addition, the ECGs 
were analyzed by one EP to limit the confusion associated with 
multiple reviewers; however, this introduced a possible rater bias. 
Lastly, the ECG leads were placed by different emergency ECG 
technicians, and the time period between ECGs varied during the 
24-hour observation period. 
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CONCLUSION
Our study demonstrates that patients presenting with acute 
chest pain to the ED often have ECG findings of LVH that are 
not reproducible. Therefore, the utility of diagnosing LVH by 
ECG in patients with acute chest pain is yet to be determined. 
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